PCSK9-IN-10 NEW
| Price | $58 | $93 | $188 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: PCSK9-IN-10 | CAS No.: 368434-98-4 |
| Purity: 99.06% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | PCSK9-IN-10 |
| Description | PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 μM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications. |
| In vitro | PCSK9-IN-10 (0, 2.5, 5, 12.5, 25 μM ; 24 h) significantly reduces PCSK9 protein expression and increases the expression of LDL receptor (LDLR) in a dose-dependent manner.[1] |
| In vivo | PCSK9-IN-10 (30 mg/kg; oral administration; once daily for 8 weeks) reduces total cholesterol (TC) levels and atherosclerotic plaque size in ApoE KO mice.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (13.39 mM), Sonication is recommended. DMSO : 250 mg/mL (669.51 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (26.78 mM), Suspension. |
| Keywords | threoninkinase | threonin kinase | Serinekinase | Serine kinase | Ser/Thr Protease | PCSK9-IN-10 | PCSK9IN10 | PCSK9 |
| Inhibitors Related | Fasudil | Bicyclol | Piceatannol | 2-Acetamidophenol | Chymotrypsin | Fasudil hydrochloride | Camostat mesylate | Moxonidine | 6-(Dimethylamino)purine | FOY 251 | Benzamidine hydrochloride | Cetraxate hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Orally Active Compound Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1820.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-07-14 | |
| $73.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-14 | |
|
VIP1Y
|
ACROBiosystems
|
2026-07-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY